Captrust Financial Advisors Decreases Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Captrust Financial Advisors decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,747 shares of the company’s stock after selling 651 shares during the period. Captrust Financial Advisors’ holdings in IDEXX Laboratories were worth $2,398,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Ridgewood Investments LLC purchased a new position in IDEXX Laboratories in the 2nd quarter valued at approximately $27,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares during the period. Strategic Investment Solutions Inc. IL purchased a new stake in IDEXX Laboratories during the 2nd quarter worth about $36,000. Finally, Ashton Thomas Securities LLC bought a new position in IDEXX Laboratories in the 3rd quarter worth about $37,000. Institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 2.11% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of a number of recent analyst reports. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday. They issued an “outperform” rating and a $500.00 price target for the company. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Barclays lowered their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $546.56.

IDEXX Laboratories Trading Down 1.6 %

Shares of IDXX stock opened at $427.49 on Friday. The business has a 50-day moving average of $445.99 and a 200 day moving average of $475.13. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The stock has a market capitalization of $35.01 billion, a PE ratio of 41.22, a P/E/G ratio of 3.95 and a beta of 1.37.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same quarter in the prior year, the firm posted $2.53 earnings per share. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.